Topic: non-small cell lung cancer
Roche knows how things work with England’s cost watchdogs, and it put that knowledge to use to score backing for Tecentriq in lung cancer.
Keytruda grew sales by 60% at constant currencies, boosting its share in Merck's portfolio. Could China and a few new indications step on the gas?
AZ's oncology portfolio jumped 59% in Q1 sales, and China turned up 28% growth. So CEO Pascal Soriot figured its time for some long-term planning.
Thanks to a new FDA green light, Keytruda is allowed in patients with low PD-L1 levels, but analysts have expressed doubts about its real-world use.
Daiichi inks $6.9 billion ADC deal with AZ, appoints new CEO; Keytruda nabs first-line lung cancer nod in China.
After a blow in first-line lung cancer, BMS is clinging to its share of the second-line market. And it’s hoping new long-term data can help it hang on.
Last AACR, Merck’s Keytruda-chemo put up stellar lung cancer data. This year, Merck was back to show the combo held up in tough-to-treat patients.
Merck's Keytruda has leaped ahead of Bristol-Myers Squibb’s Opdivo and nabbed a green light in newly diagnosed non-small cell lung cancer.
Despite pricing pressure from domestic rivals, Keytruda could still generate billions of dollars a year in China, Cantor analysts predict
AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to its cancer drugs—and once again, China.